iZafe Group (publ) hereby announces that the nomination committee proposes that Björn Rosengren be elected as the new chairman of the board at an extra general meeting. This means that Björn Rosengren is proposed to take over as new chairman after Joachim Källsholm.
Björn Rosengren has a wide range of skills and extensive experience from both business and the public sector, including as minister of business, governor and advisor to Kinnevik. Today he mainly works as a board professional in both listed and unlisted companies. Some of the companies where he is chairman of the board are Fastator, listed on Mid Cap, Studentbostäder i Norden at First North and the Norwegian-Swedish Chamber of Commerce.
"We are facing a future where the population is getting older and the pressure on healthcare is increasing. iZafe is an important piece of the puzzle to create better and safer care through medical and digital security solutions. Where I see great potential with the pharmaceutical robot Dosell on the international market. I feel both happy and honored and look forward to contributing and following the company's exciting journey forward towards new levels, says Björn Rosengren, proposed new chairman of iZafe Group.
The chairman of the selection committee, Sten Röing, comments: "Björn Rosengren has solid experience in creating value and consensus between management and owners regarding goals and priorities. We are convinced that he will contribute to continuing to develop iZafe and be involved in the work around the company's positive growth and future."
The selection committee consists of Sten Röing, Göran Sjönell and Carl Johan Merner.
The nomination committee's complete proposal will be presented in the notice to the extra general meeting.
iZafe Group (publ.) hereby announces that the partner Careium AB is today starting the implementation of Dosell in a municipality.
"As we communicated on June 8 and that in connection with delivery challenges and approaching holiday times, the majority of municipalities chose to postpone the introduction until after the summer. Now the municipalities are finally getting time to start the implementation and the first to go is our partner Careium AB. Together with our partners, we are working hard to ensure that the municipalities prioritize the start-up of our medicinal robot Dosell here this fall." Says Anders Segerström, CEO of iZafe Group
About Careium Careium is today the market leader in welfare technology in Europe and approximately 400,000 people use their services. The vast majority of these are connected to one of their six alarm centers in Sweden, Norway and the United Kingdom. The alarm centers receive more than 30,000 alarms a day. Doro Care recently changed its name to Careium. Doro acquired Caretech in 2014, which became the starting point for what today is Careium.
About Dosell The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners. In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year. Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries. Read more at www.dosell.se
iZafe Group (publ.) hereby announces that iZafe has signed a cooperation agreement with the welfare platform Avanto Care to be able to offer customers more proactive care.
"In order for future care to be able to work smart with all the advantages that digital tools provide, platforms are needed that connect all the data that the customer receives from them. Avanto Care is a platform that, in a neat and educational way, presents useful insights and action proposals linked to the data points that come in from various digital tools and sensors. In addition to providing better care, this will also in the long term enable a new type of income source for Dosell and our upcoming total solution around medication and compliance that we will offer in connection with the acquisition of Pilloxa." Says Anders Segerström CEO, iZafe Group
"The ability for caregivers and care recipients to follow medication is important for healthy ageing. We at Avanto Care see that the collaboration with iZafe and their drugrobot Dosell creates new opportunities for quality follow-up. Through the collaboration, our customers can monitor the effect of interventions and create decision-making bases for proactive interventions in health and social care." Says Mikael Karlsson, CEO, Avanto Care
The collaboration means that iZafe's products are integrated with Avanto Care's platform. This means that customers who have iZafe's products can also use Avanto Care's platform. It creates the conditions for iZafe's customers to work more proactively by seeing trends and proposed measures linked to the user's medication.
iZafe Group (publ.) has today notified the board of its decision to resign as chairman of the board for iZafe Group.
"In connection with the upcoming acquisition and the fact that I myself have many new assignments, I have finally made the choice to resign. At the stage iZafe is in now, a chairman is needed who has more time to actively work with the company than I can currently contribute. I am proud of the parts that have taken place in the past year and look forward to following iZafe's future journey. " Says Joachim Källsholm Chairman, iZafe Group
Aktieägarna i iZafe Group AB, org.nr 556762-3391 ("iZafe" eller "Bolaget"), kallas härmed till extra bolagsstämma onsdag den 28 september 2022 kl. 10.00 i iZafes lokaler på Södra Fiskartorpsvägen 20, i Stockholm.
Rätt att delta vid stämman Aktieägare som önskar delta vid stämman ska:
dels vara införd i den av Euroclear Sweden AB förda aktieboken per avstämningsdagen den 20 september 2022, (för förvaltarregistrerade aktier, se även ”Förvaltarregistrerade aktier” nedan), och
dels senast den 27 september 2022 ha anmält sitt deltagande och eventuella biträden (högst två) till Bolaget.
Anmälan kan ske skriftligen per post till iZafe Group AB, Södra Fiskartorpsvägen 20, 114 33 Stockholm, (vänligen märk kuvertet ”Extra bolagsstämma 28 september 2022”) eller per e-post till . I anmälan bör uppges fullständigt namn, person- eller organisationsnummer, aktieinnehav, aktieslag, adress, telefon-nummer samt i förekommande fall, uppgift om ställföreträdare, ombud eller biträde. Anmälan bör i förekommande fall åtföljas av fullmakter, registreringsbevis och andra behörighetshandlingar.
Förvaltarregistrerade aktier Aktieägare som har sina aktier förvaltarregistrerade hos bank eller annan förvaltare måste genom förvaltarens försorg tillfälligt låta inregistrera aktierna i eget namn för att äga rätt att delta i stämman. Sådan registrering, som normalt tar några dagar, ska vara verkställd senast den 20 september 2022 och bör därför begäras hos förvaltaren i god tid före detta datum. Rösträttsregistrering som av aktieägare har begärts i sådan tid att registreringen har gjorts av relevant förvaltare senast den 27 september 2022 kommer att beaktas vid framställningen av aktieboken.
Ombud m.m. Aktieägare som företräds genom ombud ska utfärda skriftlig och daterad fullmakt för ombudet. Om fullmakten utfärdats av juridisk person ska bestyrkt kopia av registreringsbevis, eller motsvarande behörighetshandling, utvisande att de personer som har undertecknat fullmakten är behöriga firmatecknare för den juridiska personen, bifogas fullmakten. Fullmakten får inte vara äldre än ett år gammal, dock att fullmakten får vara äldre än ett år om det framgår att den är giltig för en längre period, längst fem år. En kopia av fullmakten samt eventuellt registreringsbevis bör, för att underlätta inpasseringen vid stämman, ha kommit Bolaget tillhanda genom att insändas till Bolaget på adress enligt ovan senast den 27 september 2022. Fullmakten i original samt registreringsbevis ska även uppvisas på stämman. Fullmaktsformulär kommer finnas tillgängligt via Bolagets hemsida, www.izafegroup.com samt skickas utan kostnad till de aktieägare som begär det och uppger sin postadress. Förslag till dagordning
Bolagsstämmans öppnande
Val av ordförande för bolagsstämman
Upprättande och godkännande av röstlängd
Val av en eller två justeringspersoner
Prövning av om bolagsstämman blivit sammankallad på rätt sätt
Godkännande av dagordning
Beslut om att anta ny bolagsordning
Förslag till beslut om bemyndigande för styrelsen att besluta om nyemission av aktier, teckningsoptioner och konvertibler
Bolagsstämmans avslutande
Styrelsens beslutsförslag 2. Val av ordförande vid stämman Styrelsen föreslår att Joachim Källsholm, väljs till ordförande vid stämman.
4.Val av en eller två justeringspersoner Styrelsen föreslår att Richard Wolff väljs till justeringsperson att jämte ordföranden justera protokollet, eller, vid förhinder, sådan annan person som styrelsen anvisar.
7. Beslut om att anta ny bolagsordning Styrelsen föreslår att extra bolagsstämman godkänner styrelsens förslag till beslut om att anta ny bolagsordning enligt nedan. Ändringarna föreslås i syfte att möjliggöra det förslag till beslut om bemyndigande för styrelsen att besluta om nyemission av aktier, teckningsoptioner och konvertibler under punkt 8 på dagordningen. Ändringarna avser följande:
Nuvarande lydelse
Föreslagen lydelse
4 § Aktiekapital Aktiekapitalet ska utgöra lägst 14 000 000 kronor och högst 56 000 000 kronor.
4 § Aktiekapital Aktiekapitalet ska utgöra lägst 14 174 861,6 kr och högst 56 699 446,4 kr.
5 § Antalet aktier Antalet aktier ska vara lägst 35 427 000 och högst 141 710 800.
5 § Antalet aktier Antalet aktier ska vara lägst 70 874 308 och högst 283 497 232.
Den verkställande direktören, eller den han sätter i sitt ställe, bemyndigas att vidta de mindre justeringar i detta beslut som kan visa sig nödvändiga i samband med registrering därav. För giltigt beslut om ändring av bolagsordningen krävs att förslaget biträds av aktieägare representerande minst två tredjedelar av såväl de avgivna rösterna som de vid stämman företrädda aktierna. Beslutet är villkorat av att extra bolagsstämman fattar beslut i enlighet med punkt 8 i dagordningen och att beslutet registreras hos Bolagsverket
8. Förslag till beslut om bemyndigande för styrelsen att besluta om nyemission av aktier, teckningsoptioner och konvertibler Styrelsen föreslår att extra bolagsstämman beslutar att bemyndiga styrelsen att – vid ett eller flera tillfällen och längst intill nästkommande årsstämma – besluta om att öka Bolagets aktiekapital genom nyemission av aktier, teckningsoptioner och konvertibler inom de gränser som bolagsordningen medger. Nyemission av aktier, teckningsoptioner och konvertibler, ska kunna ske med eller utan avvikelse från aktieägarnas företrädesrätt samt med eller utan bestämmelse om apport, kvittning eller andra villkor. Enligt 16 kap. Aktiebolagslagen äger styrelsen inte med stöd av detta bemyndigande besluta om emissioner till styrelseledamöter i koncernen, anställda med flera. Emission beslutad med stöd av bemyndigandet ska ske till marknadsmässiga villkor. Syftet med bemyndigandet och skälen till eventuell avvikelse från aktieägarnas företrädesrätt är att nyemissioner av aktier, teckningsoptioner och konvertibler ska kunna ske för att öka Bolagets finansiella flexibilitet och/eller styrelsens handlingsutrymme, exempelvis i samband med strategiska förvärv av bolag och verksamheter som Bolaget kan komma att genomföra. Beslut om bemyndigandet enligt denna punkt 8 på dagordningen är villkorat av att extra bolagsstämman fattar beslut om att anta ny bolagsordning i enlighet med punkt 7 i dagordningen och att beslutet registreras hos Bolagsverket. Styrelsen föreslås bli bemyndigad att vidta de smärre justeringar i detta beslut enligt denna punkt 8 som kan komma att vara nödvändiga i samband med registrering vid Bolagsverket och vid Euroclear Sweden AB.
Majoritetsregler För giltigt beslut enligt punkt 7 och 8 krävs att beslutet biträds av aktieägare med minst två tredjedelar (2/3) av såväl av såväl de avgivna rösterna som de aktier som är företrädda vid bolagstämman.
Antalet aktier och röster I Bolaget finns vid tidpunkten för utfärdandet av denna kallelse totalt 70 874 308 aktier, varav 600 000 A-aktier och 70 274 308 B-aktier. Det totala antalet röster uppgår till 76 274 308.
Övrigt Fullmaktsformulär samt fullständiga förslag till beslut med tillhörande handlingar kommer att hållas tillgängliga senast tre veckor före stämman. Kallelsen och handlingar enligt ovan hålls tillgängliga hos Bolaget på Södra Fiskartorpsvägen 20 i Stockholm och på Bolagets webbplats www.izafegroup.com och sänds till de aktieägare som begär det och uppger sin e-mail- eller postadress. Bolagsstämmoaktieboken tillhandahålls på Bolagets kontor på ovan adress. Aktieägarna erinras om rätten att, vid extra bolagsstämman, begära upplysningar från styrelsen och verkställande direktören i enlighet med 7 kap 32 § aktiebolagslagen.
Läkemedelshanteringen på Sveriges äldreboenden brister på flera områden och är inte patientsäker. Arbetet delegeras till vård- och omsorgspersonal som saknar behörighet och många patienter får skadlig medicin. Det visar en ny undersökning från Ivo.
Inspektionen för vård och omsorg (Ivo) har granskat situationen på Sveriges särskilda boenden för äldre (Säbo) och konstaterar att det finns brister i samtliga granskade 283 kommuner. Ett bristområde är läkemedelshanteringen där var fjärde sjuksköterska uppger att de delegerar iordningställande av läkemedel i dosett till vård- och omsorgspersonal, som ofta saknar den kompetens som krävs och ofta har bristande språkkunskaper. 58 procent av de tillfrågade sjuksköterskorna ser säkerhetsrisker vid sådan delegering av läkemedelshantering. – Brister i läkemedelshantering har länge varit ett stort problem, särskilt bland våra äldre multisjuka. Det är en stor säkerhetsrisk som leder till allvarliga konsekvenser, inte bara för de drabbade och deras anhöriga utan även för samhället i stort, säger Anders Segerström, vd iZafe Group.
Stor kostnad Multisjuka äldre använder i snitt närmare tio läkemedel per dag och står för en stor del av akutintagen. Enligt Läkemedelsrådet är fyra av tio akutbesök i Sverige orsakat av felaktig läkemedelsbehandling. Det innebär en kostnad för samhället på 20 miljarder kronor per år. Ivos granskning visar också att var femte patient har läkemedel som bör undvikas bland äldre. – Det handlar inte bara om allt mänskligt lidande och ekonomiska konsekvenser som orsakas av felaktig läkemedelshantering utan det har också arbetsmiljöpåverkande konsekvenser för många sjuksköterskor. Utöver deras redan pressade arbetssituation tvingas de ofta oroa sig för om medicineringen skett på ett korrekt sett, säger Anders Segerström.
iZafe Group AB (publ.) – presents today, August 26, its report for the second quarter.
Summary of financial performance
Net sales for the quarter amounted to SEK 84 (12) thousand. The quarter's net sales consist of revenues related to the sale of the Dosell digital pharmaceutical robot.
Operating profit for the quarter amounted to SEK -5,184 (-7,962) thousand.
Profit after financial items for the quarter amounted to -5,233 (-8,258) TSEK.
Cash flow for the period amounted to SEK -7,155 (-5,400) thousand.
Earnings per share for the quarter before / after dilution amounted to SEK -0,1 (-0,2).
Equity per share at the end of the period amounted to SEK 0,4 (0,4).
The equity/assets ratio at the end of the period was 81.8 (39.5) percent.
Significant events in the quarter
The company has launched an updated version of Dosell that includes several new improvements and features that enhance both the user experience and reliability.
During the month of June, the company has delivered a large batch to Apoteket AB, which has had a high demand for the company's products and has sold out of its stock.
Significant events after the end of the quarter
iZafe signs a Letter of Intent to acquire Pilloxa AB. Pilloxa has developed a technical platform for improved adherence that pharmaceutical companies use to design digital patient support. The purchase price will be paid in 70,874,308 newly issued iZafe shares with an indicative value of approximately 30 million SEK.
COMMENTS FROM THE CEO Our vision is to ensure health through better adherence and in the last quarter we have taken an even bigger step through our updated vision and strategy presented in May.
During the second quarter, we focused on consumer advertising, which continues to deliver good results and improved Dosell's performance. At the same time, we are seeing increased interest among municipalities in both pharmaceutical robots and the data they can bring to medication management. After the end of the quarter, we announced a letter of intent to acquire Pilloxa AB. The acquisition of Pilloxa creates a unique position in digital health With the acquisition of Pilloxa, we have the opportunity to create a more comprehensive offering that meets the different needs of consumers, from independent medication management to the choice of a smart connected pillbox or a fully automated medication robot.
The acquisition of Pilloxa also gives us access to additional sales channels as we complement each other very well. Pilloxa has had pharmaceutical companies as its primary customer group and has developed a unique SaaS solution as well as support for the conduct of clinical studies. Immediately after the acquisition, we will start the journey towards making Pilloxa's solution more commercially viable in our existing sales channels.
Pilloxa's employees and the expertise they bring, are an important part of the acquisition. They come in with the right kind of knowledge and the experience we need to create a company that takes the position of being the leader in the market to ensure adherence to medication and ultimately, to demonstrate the health benefits of it. We are working to optimize our organization to cut costs and prepare for a future merge.
The company is continuing discussions with investors, who are keen to see more acquisitions and organic growth in a market that is largely untapped. Following our communication regarding the acquisition of Pilloxa, interest has increased further – which is positive for future funding of the company in addition to the warrant program TO10B which, depending on the stock price, will provide a better capital contribution. B2C – continual increased sales and the potential outside Sweden In recent months, we have invested in television advertising to spread awareness of Dosell. As a result, we now sell around 100 units a month via the Apoteket website and the consumer version of Dosell accounts for around 90% of all dispensations today. This is a very good start for a brand-new type of product and service, but not enough and hence need to find more ways to get higher volumes out.
Our investment here in Sweden with the consumer version of Dosell has been crucial in creating the experience and knowledge needed to export the solution to other countries and markets. In all dialogues with potential partners, there has also been interest in our vision's future solutions, which we will now be able to sell and distribute much more quickly in connection with the acquisition of Pilloxa.
However, the concept in Italy continues with delays due to production and software changes. The Italian market has great potential where we see great advantages in the customer being able to have their medicines packaged in sachet bags directly by the local pharmacy together with their Dosell. In the Swedish market this is a challenge where we see long lead times to get their medicines in sachet bags if they do not already use it when they have bought their Dosell. Therefore, we see great potential in the Italian concept, which is also applicable to more markets in Europe. B2B – interest in medication data We see a clear trend that more municipalities are starting to demand pharmaceutical robots, with many tenders just coming out in both Sweden and Norway.
We have also noticed strong demand from welfare platforms that want to get data on medication. With the acquisition of Pilloxa, this becomes a complete solution for welfare platforms as we can provide even more data around medication adherence.
Continuous improvement We are constantly working to improve Dosell's performance. As we communicated in the spring, we had production challenges and a software release that included improvements necessary for our partners to deploy their Dosell in the field. These elements were completed too late into the summer holidays and as a result our partners are now able to go live after the summer months.
We have an exciting and intense period ahead of us. Our many partners and customers will start up the use of Dosell, we will finalize all the elements around the acquisition and ensure to develop an attractive joint future offering.
iZafe Group AB (publ) – announces that in connection with the interim report for the second quarter of 2022, which will be published at 08:30 CET on August 26, 2022, shareholders, media, and other stakeholders will be given the opportunity to ask questions to the company.
The questions will be answered by CEO Anders Segerström and published on iZafe Group's investor page on September 2, 2022, under the heading financial reports, investor questions. Please send your questions to before 10:00 CET (10 a.m.) on August 30, 2022.
iZafe Group (publ.) hereby invites you to a live interview with Pilloxa's CEO Helena Rönnqvist and iZafe Group's CEO Anders Segerström on Wednesday, August 24 at 2 p.m. due to the fact that iZafe has signed a letter of intent with Pilloxa to acquire 100 percent of the shares in Pilloxa.
During the interview, all shareholders and stakeholders will get a more in-depth understanding of the rationale behind the acquisition, about Pilloxa as a company and what the acquisition means for the future iZafe Group.
iZafe Group AB (publ) ("iZafe" or the "Company") has signed a Letter of Intent with Pilloxa AB ("Pilloxa") regarding the acquisition of 100 percent of the shares in Pilloxa (the "Acquisition"). Pilloxa has developed a technical platform for better compliance that pharmaceutical companies use to design digital patient support. A new company within digital health is created through the acquisition that is well positioned to become a leading company within better and more secure use of pharmaceuticals.
The Letter of Intent concerns 100 percent of the shares in Pilloxa. The purchase price is paid at 100 percent of 70,874,308 newly issued iZafe shares at an indicative value of approximately SEK 30 million. The indicative value of Pilloxa may be adjusted upwards or downwards depending on the development of the share price on the day of entry. Given that the indicative offer is accepted, the shareholders in Pilloxa will own 50 percent of the shares in the joint company after the takeover, which is expected to take place during Q3 2022. The acquisition is subject to approval at an extraordinary general meeting of iZafe Group AB. More information about the extraordinary general meeting will be published in a separate press release.
– For a long time, we have developed the drug dispensing robot Dosell and established a network of partners and collaborations that see great value in medication data to enable proactive care. Through the acquisition of Pilloxa, we are now taking the next step towards our vision of improved health with better compliance, whose digital platform can be leveraged and integrated directly into our existing products and offerings. It creates an attractive and complete offer, access to a larger customer base and additional sales channels. Together we are creating something unique within the framework of digital health, says Anders Segerström, CEO of iZafe.
– With Pilloxa's digital offering and long-term collaboration with the pharmaceutical industry and together with iZafe, we are able to offer a comprehensive solution for our customers; patients, healthcare professionals and the pharmaceutical industry. Pilloxa's promise to our customers today is a complete digital solution for patient support within one month of the initiation meeting. We are therefore used to rapid integrations and will immediately begin to work on offering a joint digital solution, says Helena Rönnqvist, CEO of Pilloxa.
Incorrect or inadequate medication is a major and expensive problem for both the individual and drug development companies and costs society significant sums. Offering patients support to take their medication correctly has been shown to be an effective way to achieve better medical outcomes. Both iZafe and Pilloxa today offer solutions that support patients in safe medical treatment. The merger means a broader and attractive offer to both healthcare providers, the pharmaceutical industry and consumers, broadens the customer base and is expected to contribute to accelerated market penetration through clear sales and margin synergies.
About Pilloxa Pilloxa is a Swedish company that develops apps for patients to support them in adherence to their treatment and to connect patients, healthcare providers and the pharmaceutical industry. The company provides a SaaS platform where pharmaceutical companies and other customers can design digital patient support quickly, securely and at a low cost. Connected aids such as Pilloxa's self-developed smart medication dose can also be connected to the service to support patients in taking the correct medication. Customers and partners of Pilloxa include pharmaceutical companies such as Bayer Nordics and the Nordic office of Chiesi Global Rare Diseases, university hospitals such as the University Hospital in Oslo and universities such as the University of Gothenburg.
Advisor Mangold Fondkommission AB is the financial advisor to iZafe in connection with the Acquisition.
